Skip to main content
Erschienen in: Cancer Chemotherapy and Pharmacology 6/2005

01.12.2005 | Original Article

Signal transduction through substance P receptor in human glioblastoma cells: roles for Src and PKCδ

verfasst von: Keisuke Yamaguchi, Mark D. Richardson, Darrell D. Bigner, Madan M. Kwatra

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 6/2005

Einloggen, um Zugang zu erhalten

Abstract

Substance P receptor (SPR), a G protein-coupled receptor (GPCR), is found in human glioblastomas, and has been implicated in their growth. Consistent with a role for SPR in cell growth, activation of SPR in U373 MG human glioblastoma cells leads to the phosphorylation of mitogen-activated protein kinases [extracellular signal-regulated kinase 1 and 2 (ERK1/2)] and stimulation of cell proliferation. The purpose of the present study was to elucidate the pathway through which these actions occur. Using either the epidermal growth factor receptor (EGFR) kinase inhibitor, AG 1478, or a small-interfering RNA (siRNA) directed against human EGFR, we found that transactivation of EGFR by SPR is only marginally involved in SP-dependent ERK1/2 phosphorylation. Src, however, is shown to be a major component of SPR signaling because the Src kinase inhibitor, PP2, and a kinase-dead Src mutant both inhibit SP-dependent ERK1/2 phosphorylation. We also report that SPR stimulates the phosphorylation of protein kinase Cδ(PKCδ), and that this stimulation is blocked by PP2. SP-dependent ERK1/2 phosphorylation is also blocked by rottlerin, a PKCδ inhibitor, and the calcium scavenger, BAPTA/AM. Finally, rottlerin and PP2 were both found to inhibit the growth of several glioblastoma cell lines, underscoring the potential of these agents to block glioblastoma growth.
Literatur
1.
Zurück zum Zitat Otsuka M, Yoshioka K (1993) Neurotransmitter functions of mammalian tachykinins. Physiol Rev 73:229–308PubMed Otsuka M, Yoshioka K (1993) Neurotransmitter functions of mammalian tachykinins. Physiol Rev 73:229–308PubMed
2.
Zurück zum Zitat Palma C, Maggi CA (2000) The role of tachykinins via NK1 receptors in progression of human gliomas. Life Sci 67:985–1001PubMed Palma C, Maggi CA (2000) The role of tachykinins via NK1 receptors in progression of human gliomas. Life Sci 67:985–1001PubMed
3.
Zurück zum Zitat Hennig IM, Laissue JA, Horisberger U, Reubi JC (1995) Substance-P receptors in human primary neoplasms: tumoral and vascular localization. Int J Cancer 61:786–792PubMed Hennig IM, Laissue JA, Horisberger U, Reubi JC (1995) Substance-P receptors in human primary neoplasms: tumoral and vascular localization. Int J Cancer 61:786–792PubMed
4.
Zurück zum Zitat Luo W, Sharif TR, Sharif M (1996) Substance P-induced mitogenesis in human astrocytoma cells correlates with activation of the mitogen-activated protein kinase signaling pathway. Cancer Res 56: 4983–4991PubMed Luo W, Sharif TR, Sharif M (1996) Substance P-induced mitogenesis in human astrocytoma cells correlates with activation of the mitogen-activated protein kinase signaling pathway. Cancer Res 56: 4983–4991PubMed
5.
Zurück zum Zitat Palma C, Nardelli F, Manzini S, Maggi CA (1999) Substance P activates responses correlated with tumour growth in human glioma lines bearing tachykinin NK1 receptors. Br J Pharmacol 79:236–243 Palma C, Nardelli F, Manzini S, Maggi CA (1999) Substance P activates responses correlated with tumour growth in human glioma lines bearing tachykinin NK1 receptors. Br J Pharmacol 79:236–243
6.
Zurück zum Zitat Palma C, Goso C, Manzini S (1994) Different susceptibility to neurokinin 1 receptor antagonists of substance P and septide-induced interleukin-6 release from U373 MG human astrocytoma cell line. Neurosci Lett 171:221–224PubMed Palma C, Goso C, Manzini S (1994) Different susceptibility to neurokinin 1 receptor antagonists of substance P and septide-induced interleukin-6 release from U373 MG human astrocytoma cell line. Neurosci Lett 171:221–224PubMed
7.
Zurück zum Zitat Gillespie GY (1996) Cytokines as modulators of malignant glioma progression. In: Ransohoff RM, Beneviste EM (eds) Cytokines and the CNS.CRC Press, Boca Raton, pp 269–286 Gillespie GY (1996) Cytokines as modulators of malignant glioma progression. In: Ransohoff RM, Beneviste EM (eds) Cytokines and the CNS.CRC Press, Boca Raton, pp 269–286
8.
Zurück zum Zitat Johnson CL, Johnson CG (1992) Characterization of receptors for substance P in human astrocytoma cells: radioligand binding and inositol phosphate formation. J Neurochem 58:471–477PubMed Johnson CL, Johnson CG (1992) Characterization of receptors for substance P in human astrocytoma cells: radioligand binding and inositol phosphate formation. J Neurochem 58:471–477PubMed
9.
Zurück zum Zitat Luo W, Sharif TR, Houghton PJ, Sharif M (1997) CGP 4125 and tamoxifen selectively inhibit mitogen-activated protein kinase activation and c-Fos phosphoprotein induction by substance P in human astrocytoma cells. Cell Growth Diff 8:1225–1240PubMed Luo W, Sharif TR, Houghton PJ, Sharif M (1997) CGP 4125 and tamoxifen selectively inhibit mitogen-activated protein kinase activation and c-Fos phosphoprotein induction by substance P in human astrocytoma cells. Cell Growth Diff 8:1225–1240PubMed
10.
Zurück zum Zitat Fiebich BL, Schleicher S, Butcher RD, Craig A, Lieb K (2000) The neuropeptide substance P activates p38 mitogen-activated protein kinase resulting in IL-6 expression independently from NF-κB. J Immunol 165:5606–5611PubMed Fiebich BL, Schleicher S, Butcher RD, Craig A, Lieb K (2000) The neuropeptide substance P activates p38 mitogen-activated protein kinase resulting in IL-6 expression independently from NF-κB. J Immunol 165:5606–5611PubMed
11.
Zurück zum Zitat Lieb K, Fiebich BL, Berger M, Bauer J, Schulze-Osthoff K (1997) The neuropeptide substance P activates transcription factor NF-kappa B and kappa B-dependent gene expression in human astrocytoma cells. J Immunol 159:4952–4958PubMed Lieb K, Fiebich BL, Berger M, Bauer J, Schulze-Osthoff K (1997) The neuropeptide substance P activates transcription factor NF-kappa B and kappa B-dependent gene expression in human astrocytoma cells. J Immunol 159:4952–4958PubMed
12.
Zurück zum Zitat Castagliuolo I, Valenick L, Liu J, Pothoulakis C (2000) Epidermal growth factor receptor transactivation mediates substance P-induced mitogenic responses in U-373 MG cells. J Biol Chem 275:26545–26550PubMed Castagliuolo I, Valenick L, Liu J, Pothoulakis C (2000) Epidermal growth factor receptor transactivation mediates substance P-induced mitogenic responses in U-373 MG cells. J Biol Chem 275:26545–26550PubMed
13.
Zurück zum Zitat Miller WE, Maudsley S, Ahn S, Khan KD, Luttrell LM, Lefkowitz RJ (2000) β-Arrestin1 interacts with the catalytic domain of the tyrosine kinase c-SRC. J Biol Chem 275:11312–11319PubMed Miller WE, Maudsley S, Ahn S, Khan KD, Luttrell LM, Lefkowitz RJ (2000) β-Arrestin1 interacts with the catalytic domain of the tyrosine kinase c-SRC. J Biol Chem 275:11312–11319PubMed
14.
Zurück zum Zitat Roush ED, Warabi K, Kwatra MM (1999) Characterization of differences between rapid agonist-dependent phosphorylation and phorbol ester-mediated phosphorylation of human substance P receptor in intact cells. Mol Pharmacol 55:855–862PubMed Roush ED, Warabi K, Kwatra MM (1999) Characterization of differences between rapid agonist-dependent phosphorylation and phorbol ester-mediated phosphorylation of human substance P receptor in intact cells. Mol Pharmacol 55:855–862PubMed
15.
Zurück zum Zitat Roush ED, Kwatra MM (1998) Human substance P receptor expressed in Chinese hamster ovary cells directly activates Gαq/11, Gαs, and Gαo. FEBS Lett 428:291–294PubMed Roush ED, Kwatra MM (1998) Human substance P receptor expressed in Chinese hamster ovary cells directly activates Gαq/11, Gαs, and Gαo. FEBS Lett 428:291–294PubMed
16.
Zurück zum Zitat Pierce KL, Luttrell LM, Lefkowitz RJ (2001) New mechanisms in heptahelical receptor signaling to mitogen activated protein kinase cascades. Oncogene 20:1532–1539PubMed Pierce KL, Luttrell LM, Lefkowitz RJ (2001) New mechanisms in heptahelical receptor signaling to mitogen activated protein kinase cascades. Oncogene 20:1532–1539PubMed
17.
Zurück zum Zitat DeFea KA, Vaughn ZD, O’Bryan EM, Nishijima D, Déry O, Bunnett NW (2000) The antiproliferative and antiapoptotic effects of substance P are facilitated by formation of a β-arrestin-dependent scaffolding complex. Proc Natl Acad Sci USA 97:11086–11091PubMed DeFea KA, Vaughn ZD, O’Bryan EM, Nishijima D, Déry O, Bunnett NW (2000) The antiproliferative and antiapoptotic effects of substance P are facilitated by formation of a β-arrestin-dependent scaffolding complex. Proc Natl Acad Sci USA 97:11086–11091PubMed
18.
Zurück zum Zitat Traxler P, Bold G, Frei J, Lang N, Mett H, Buchdunger E, Meyer T, Mueller M, Furet P (1997) Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo[3,4-d]pyrimidines. J Med Chem 40:3601–3616PubMed Traxler P, Bold G, Frei J, Lang N, Mett H, Buchdunger E, Meyer T, Mueller M, Furet P (1997) Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo[3,4-d]pyrimidines. J Med Chem 40:3601–3616PubMed
19.
Zurück zum Zitat Benes C, Soltoff SP (2001) Modulation of PKCδ tyrosine phosphorylation and activity in salivary and PC-12 cells by Src kinases. Am J Physiol Cell Physiol 280:C1498–C1510PubMed Benes C, Soltoff SP (2001) Modulation of PKCδ tyrosine phosphorylation and activity in salivary and PC-12 cells by Src kinases. Am J Physiol Cell Physiol 280:C1498–C1510PubMed
20.
Zurück zum Zitat Tapia JA, García-Marin LJ, Jensen RT (2003) Cholecystokinin-stimulated protein kinase C-δ kinase activation, tyrosine phosphorylation, and translocation are mediated by Src tyrosine kinases in pancreatic acinar cells. J Biol Chem 278:35220–35230PubMed Tapia JA, García-Marin LJ, Jensen RT (2003) Cholecystokinin-stimulated protein kinase C-δ kinase activation, tyrosine phosphorylation, and translocation are mediated by Src tyrosine kinases in pancreatic acinar cells. J Biol Chem 278:35220–35230PubMed
21.
Zurück zum Zitat Robin P, Boulven I, Bole-Feysot C, Tanfin Z, Leiber D (2004) Contribution of PKC-dependent and -independent processes in temporal ERK regulation by ET-1, PDGF, and EGF in rat myometrial cells. Am J Physiol Cell Physiol 286:C798–C806PubMed Robin P, Boulven I, Bole-Feysot C, Tanfin Z, Leiber D (2004) Contribution of PKC-dependent and -independent processes in temporal ERK regulation by ET-1, PDGF, and EGF in rat myometrial cells. Am J Physiol Cell Physiol 286:C798–C806PubMed
22.
Zurück zum Zitat Greco S, Muscella A, Elia MG, Romano S, Storelli C, Marsigliante S (2004) Mitogenic signalling by B2 bradykinin receptor in epithelial breast cells. J Cell Physiol 201:84–96PubMed Greco S, Muscella A, Elia MG, Romano S, Storelli C, Marsigliante S (2004) Mitogenic signalling by B2 bradykinin receptor in epithelial breast cells. J Cell Physiol 201:84–96PubMed
23.
Zurück zum Zitat Treiman M, Caspersen C, Christensen SB (1998) A tool coming of age: thapsigargin as an inhibitor of sarco-endoplasmic reticulum Ca2+-ATPases. Trends Pharmacol Sci 19:131–135PubMed Treiman M, Caspersen C, Christensen SB (1998) A tool coming of age: thapsigargin as an inhibitor of sarco-endoplasmic reticulum Ca2+-ATPases. Trends Pharmacol Sci 19:131–135PubMed
24.
Zurück zum Zitat Parmer TG, Ward MD, Hait WN (1997) Effects of rottlerin, an inhibitor of calmodulin-dependent protein kinase III, on cellular proliferation, viability, and cell cycle distribution in malignant glioma cells. Cell Growth Diff 8:327–334PubMed Parmer TG, Ward MD, Hait WN (1997) Effects of rottlerin, an inhibitor of calmodulin-dependent protein kinase III, on cellular proliferation, viability, and cell cycle distribution in malignant glioma cells. Cell Growth Diff 8:327–334PubMed
25.
Zurück zum Zitat Biscardi JS, Tice DA, Parsons SJ (1999) c-Src, receptor tyrosine kinases and human cancer. Adv Cancer Res 76:61–119PubMed Biscardi JS, Tice DA, Parsons SJ (1999) c-Src, receptor tyrosine kinases and human cancer. Adv Cancer Res 76:61–119PubMed
26.
Zurück zum Zitat Staley CA, Parikh NU, Gallick GE (1997) Decreased tumorigenicity of a human colon adenocarcinoma cell line by an antisense expression vector specific for c-Src. Cell Growth Diff 8:269–274PubMed Staley CA, Parikh NU, Gallick GE (1997) Decreased tumorigenicity of a human colon adenocarcinoma cell line by an antisense expression vector specific for c-Src. Cell Growth Diff 8:269–274PubMed
27.
Zurück zum Zitat Irby RB, Mao W, Coppola D, Kang J, Loubeau JM, Trudeau W, Karl R, Fujita DJ, Jove R, Yeatman TJ (1999) Activating SRC mutation in a subset of advanced human colon cancers. Nat Genet 21:187–190PubMed Irby RB, Mao W, Coppola D, Kang J, Loubeau JM, Trudeau W, Karl R, Fujita DJ, Jove R, Yeatman TJ (1999) Activating SRC mutation in a subset of advanced human colon cancers. Nat Genet 21:187–190PubMed
28.
Zurück zum Zitat Susa M, Missbach M, Green J (2000) Src inhibitors: drugs for the treatment of osteoporosis, cancer or both. Trends Pharmacol Sci 21: 489–495PubMed Susa M, Missbach M, Green J (2000) Src inhibitors: drugs for the treatment of osteoporosis, cancer or both. Trends Pharmacol Sci 21: 489–495PubMed
29.
Zurück zum Zitat Yeatman TJ (2004) A renaissance for Src. Nat Rev Cancer 4: 470–480PubMed Yeatman TJ (2004) A renaissance for Src. Nat Rev Cancer 4: 470–480PubMed
30.
Zurück zum Zitat Rosen N, Bolen JB, Schwartz AM, Cohen P, DeSeau V, Israel MA (1986) Analysis of pp60c-src protein kinase activity in human tumor cell lines and tissues. J Biol Chem 261:13754–13759PubMed Rosen N, Bolen JB, Schwartz AM, Cohen P, DeSeau V, Israel MA (1986) Analysis of pp60c-src protein kinase activity in human tumor cell lines and tissues. J Biol Chem 261:13754–13759PubMed
31.
Zurück zum Zitat Hussaini IM, Karns LR, Vinton G, Carpenter JE, Redpath GT, Sando JJ, VandenBerg SR (2000) Phorbol 12-myristate 13-acetate induces protein kinase Cη - specific proliferative response in astrocytic tumor cells. J Biol Chem 275:22348–22354PubMed Hussaini IM, Karns LR, Vinton G, Carpenter JE, Redpath GT, Sando JJ, VandenBerg SR (2000) Phorbol 12-myristate 13-acetate induces protein kinase Cη - specific proliferative response in astrocytic tumor cells. J Biol Chem 275:22348–22354PubMed
32.
Zurück zum Zitat Mandil R, Ashkenazi E, Blass M, Kronfeld I, Kazimirsky G, Rosenthal G, Umansky F, Lorenzo PS, Blumberg PM, Brodie C (2001) Protein kinase Cα and protein kinase Cδ play opposite roles in proliferation and apoptosis of glioma cells. Cancer Res 61:4612–4619PubMed Mandil R, Ashkenazi E, Blass M, Kronfeld I, Kazimirsky G, Rosenthal G, Umansky F, Lorenzo PS, Blumberg PM, Brodie C (2001) Protein kinase Cα and protein kinase Cδ play opposite roles in proliferation and apoptosis of glioma cells. Cancer Res 61:4612–4619PubMed
33.
Zurück zum Zitat Zrachia A, Dobroslav M, Blass M, Kazimirsky G, Kronfeld I, Blumberg PM, Kobiler D, Lustig S, Brodie C (2002) Infection of glioma cells with sindbis virus induces selective activation and tyrosine phosphorylation of protein kinase Cδ. J Biol Chem 277:23693–23701PubMed Zrachia A, Dobroslav M, Blass M, Kazimirsky G, Kronfeld I, Blumberg PM, Kobiler D, Lustig S, Brodie C (2002) Infection of glioma cells with sindbis virus induces selective activation and tyrosine phosphorylation of protein kinase Cδ. J Biol Chem 277:23693–23701PubMed
34.
Zurück zum Zitat Kambhampati S, Li Y, Verma A, Sassano A, Majchrzak B, Deb DK, Parmer S, Giafis N, Kalvakolanu DV, Rahman A, Uddin S, Minucci S, Tallman MS, Fish EN, Platanias LC (2003) Activation of protein kinase Cδ by all-trans-retinoic acid. J Biol Chem 278:32544–32551PubMed Kambhampati S, Li Y, Verma A, Sassano A, Majchrzak B, Deb DK, Parmer S, Giafis N, Kalvakolanu DV, Rahman A, Uddin S, Minucci S, Tallman MS, Fish EN, Platanias LC (2003) Activation of protein kinase Cδ by all-trans-retinoic acid. J Biol Chem 278:32544–32551PubMed
35.
Zurück zum Zitat Li W, Jiang Y-X, Zhang J, Soon L, Flechner L, Kapoor V, Pierce JH, Wang L-H (1998) Protein kinase C-δ is an important signaling molecule in insulin-like growth factor I receptor-mediated cell transformation. Mol Cell Biol 18:5888–5898PubMed Li W, Jiang Y-X, Zhang J, Soon L, Flechner L, Kapoor V, Pierce JH, Wang L-H (1998) Protein kinase C-δ is an important signaling molecule in insulin-like growth factor I receptor-mediated cell transformation. Mol Cell Biol 18:5888–5898PubMed
36.
Zurück zum Zitat Jackson DN, Foster DA (2004) The enigmatic protein kinase Cδ: complex roles in cell proliferation and survival. FASEB J 18:627–636PubMed Jackson DN, Foster DA (2004) The enigmatic protein kinase Cδ: complex roles in cell proliferation and survival. FASEB J 18:627–636PubMed
37.
Zurück zum Zitat Ginnan R, Pfleiderer PJ, Pumiglia K, Singer HA (2004) PKC- and CaMKII-δ2 mediate ATP-dependent activation of ERK1/2 in vascular smooth muscle. Am J Physiol Cell Physiol 286:C1281–C1289PubMed Ginnan R, Pfleiderer PJ, Pumiglia K, Singer HA (2004) PKC- and CaMKII-δ2 mediate ATP-dependent activation of ERK1/2 in vascular smooth muscle. Am J Physiol Cell Physiol 286:C1281–C1289PubMed
38.
Zurück zum Zitat Gschwendt M, Müller H-J, Kielbassa K, Zang R, Kittstein W, Rincke G, Marks F (1994) Rottlerin, a novel protein kinase inhibitor. Bioch Biochem Biophys Res Commun 199:93–98PubMed Gschwendt M, Müller H-J, Kielbassa K, Zang R, Kittstein W, Rincke G, Marks F (1994) Rottlerin, a novel protein kinase inhibitor. Bioch Biochem Biophys Res Commun 199:93–98PubMed
39.
Zurück zum Zitat Nagane M, Narita Y, Mishima K, Levitzki A, Burgess AW, Cavenee WK, Huang HJ (2001) Human glioblastoma xenografts overexpressing a tumor-specific mutant epidermal growth factor receptor sensitized to cisplatin by the AG1478 tyrosine kinase inhibitor. J Neurosurg 95: 472–479PubMed Nagane M, Narita Y, Mishima K, Levitzki A, Burgess AW, Cavenee WK, Huang HJ (2001) Human glioblastoma xenografts overexpressing a tumor-specific mutant epidermal growth factor receptor sensitized to cisplatin by the AG1478 tyrosine kinase inhibitor. J Neurosurg 95: 472–479PubMed
40.
Zurück zum Zitat Efferth T, Ramirez T, Gebhart E, Halatsch ME (2004) Combination treatment of glioblastoma multiforme cell lines with the anti-malarial artesunate and epidermal growth factor receptor tyrosine kinase inhibitor OSI-774. Biochem Pharmacol 67:1689–1700PubMed Efferth T, Ramirez T, Gebhart E, Halatsch ME (2004) Combination treatment of glioblastoma multiforme cell lines with the anti-malarial artesunate and epidermal growth factor receptor tyrosine kinase inhibitor OSI-774. Biochem Pharmacol 67:1689–1700PubMed
Metadaten
Titel
Signal transduction through substance P receptor in human glioblastoma cells: roles for Src and PKCδ
verfasst von
Keisuke Yamaguchi
Mark D. Richardson
Darrell D. Bigner
Madan M. Kwatra
Publikationsdatum
01.12.2005
Erschienen in
Cancer Chemotherapy and Pharmacology / Ausgabe 6/2005
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-005-1030-3

Weitere Artikel der Ausgabe 6/2005

Cancer Chemotherapy and Pharmacology 6/2005 Zur Ausgabe

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.